Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KuDOS Pharmaceuticals Ltd.

Division of AstraZeneca PLC
www.kudospharma.co.uk

Latest From KuDOS Pharmaceuticals Ltd.

Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic

Cambridge, UK-based Artios Pharma attracted several new investors for its over-subscribed series B round in August 2018, but the company is yet to enter the clinic with its DNA repair drug portfolio and has many hurdles ahead to validate its technology. Scrip speaks to investors from LSP and Arix about why preclinical-stage biotechs are getting more attention in 2018.

Companies Financing

Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
Financing Cancer

Appointments: Piramal Pharma, Oxeia, Artios Eyevensys and Bone Therapeutics

This week's roundup includes a new CEO for Oxeia, in addition to various other high-level appointments by Piramal Pharma Solutions, Bone Therapeutics, Kiadis and biOasis. Artios Pharma also welcomes AstraZeneca's former senior director bioscience, oncology to its team.

Appointments BioPharmaceutical

Making The Most Of A Maturing Myriad Genetics

Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.

Medical Device BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Barrie Ward, PhD, CEO
    David Dally, CFO
    Stephen Jackson, CSO
  • Contact Info
  • KuDOS Pharmaceuticals Ltd.
    Phone: (44) 1223 719 719
    410 Cambridge Science Park
    Milton Road
    Cambridge, CB4 0PE
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register